Aclidinium bromide provides long-acting bronchodilation in patients with COPD

Pulmonary Pharmacology and Therapeutics

Volumn 23, Issue 1, 2010, Pages 15-21

  Chanez, P ^a   Burge, P S ^b   Dahl, R ^c   Creemers, J ^d   Chuchalin, A ^e   Lamarca, R ^f   Garcia Gil, E ^f  

^a AIX MARSEILLE UNIVERSITY   (France)

^b BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d CATHARINA HOSPITAL   (Netherlands)

^e PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^f Almirall Prodesfarma S A   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACLIDINIUM BROMIDE; ANTIHISTAMINIC AGENT; CORTICOSTEROID; KETOTIFEN; NEDOCROMIL; PLACEBO; SALBUTAMOL; THEOPHYLLINE; TIOTROPIUM BROMIDE;

ADULT; ARTICLE; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CYSTITIS; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ELECTROCARDIOGRAM; EXTRASYSTOLE; FATIGUE; FEMALE; FORCED EXPIRATORY VOLUME; GLUCOSE BLOOD LEVEL; HOARSENESS; HUMAN; HYPERTENSION; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SIDE EFFECT; SPIROMETRY; XEROSTOMIA;

AGED; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TROPANES; VITAL CAPACITY;

EID: 74649085382     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2009.08.001     Document Type: Article

References (15)

1. Rabe K.F., Hurd S., Anzueto A., Barnes P.J., Buist S.A., Calverley P., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 176 (2007) 532-555
2. Murray C.J., and Lopez A.D. Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study. Lancet 349 (1997) 1498-1504
3. Lopez A.D., Shibuya K., Rao C., Mathers C.D., Hansell A.L., Held L.S., et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 27 (2006) 397-412
4. Engstrom C.P., Persson L.O., Larsson S., Ryden A., and Sullivan M. Functional status and well being in chronic obstructive pulmonary disease with regard to clinical parameters and smoking: a descriptive and comparative study. Thorax 51 (1996) 825-830
5. Domingo-Salvany A., Lamarca R., Ferrer M., Garcia-Aymerich J., Alonso J., Felez M., et al. Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 166 (2002) 680-685
6. Gavalda A., Miralpeix M., Ramos I., Vilella D., Sentellas S., Alberti J., et al. Aclidinium bromide, a novel muscarinic receptor combining long residence at M3 receptors and rapid plasma clearance. Eur Respir J 30 Suppl. 51 (2007) 209S-210S
7. Schelfhout V.J., Joos G.F., Garcia Gil E., and Montejo E.M. Bronchodilator/bronchoprotective effects of aclidinium bromide, a novel long-acting anticholinergic: a phase I study. Eur Respir J 30 Suppl. 51 (2007) 356S
8. Joos G.F., Schelfhout V.J., Kanniess F., Ludwig-Sengpill A., Garcia Gil E., and Montejo E.M. Bronchodilator effects of aclidinium bromide, a novel long-acting anticholinergic, in COPD patients: a phase II study. Eur Respir J 30 Suppl. 51 (2007) 210S
9. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 152 (1995) S77-S120
10. Greguletz R., Arlt M., Anke S., Goede J., Haaije de Boer A., and Frijlink H.W. A novel multidose dry powder inhaler for the delivery of various types of inhalation powder. Am J Respir Crit Care Med 179 (2009) A2461
11. Quanjer P.H., Tammeling G.J., Cotes J.E., Pedersen O.F., Peslin R., and Yernault J.C. Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, European community for steel and coal. Official statement of the European respiratory society. Eur Respir J Suppl 16 (1993) 5-40
12. Pellegrino R., Viegi G., Brusasco V., Crapo R.O., Burgos F., Casaburi R., et al. Interpretative strategies for lung function tests. Eur Respir J 26 (2006) 948-968
13. Miller M.R., Hankinson J., Brusasco V., Burgos F., Casaburi R., Coates A., et al. Standardisation of spirometry. Eur Respir J 26 (2005) 319-338
14. Abrams P., Andersson K.E., Buccafusco J.J., Chapple C., de Groat W.C., Fryer A.D., et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 148 (2006) 565-578
15. Tashkin D.P., Celli B., Decramer M., Liu D., Burkhart D., Cassino C., et al. Bronchodilator responsiveness in patients with COPD. Eur Respir J 31 (2008) 742-750